Drugs / AAV2CUhCLN2
AAV2CUhCLN2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00151216 | Jun 2004 → Jun 2019 | late infantile neuronal ceroid lipofuscinosis, lysosomal lipid storage disorder | Weill Medical College of Cornell University | Completed | Met primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AAV2 CU h-CLN2 | “an adeno-associated virus (AAV) serotype 2 vector expressing the human CLN2 cDNA (AAV2 CU h-CLN2)” PMID 18473686 ↗ May 2008 |
| Modality | Gene therapy (AAV / viral vector) | “an adeno-associated virus vector encoding the normal human CLN2 gene (AAV2CUhCLN2)” NCT00151216 ↗ |
| Route | Other | “Following direct intracranial administration of the vector” NCT00151216 ↗ |
| Target | CLN2 | “an adeno-associated virus vector encoding the normal human CLN2 gene (AAV2CUhCLN2)” NCT00151216 ↗ |